Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 15 November 2016 | By Michael Mezher
The US Food and Drug Administration (FDA) on Tuesday said it has approved new labeling for Bayer's permanent birth control device Essure, in line with the agency's recently finalized labeling guidance.
With the approval of the new labeling, FDA said it has also closed its investigation of a trade complaint, initially filed as a citizen petition, against Bayer concerning the device.
FDA spokesperson Angela Stark told Focus the investigation included a review of Essure's labeling, as well as "inspections of Bayer, including surveillance of ongoing clinical investigations related to the Essure device, to ensure that the manufacturer was complying with FDA's laws and regulations."
According to Stark, the language of the box warning in the new label is the same as the wording used in the agency's final guidance:
Stark also told Focus that the patient decision checklist included in the newly approved labeling is not identical to the example in the final guidance, but that it was consistent with the agency's aims for the checklist.
"The Essure Patient Decision Checklist was evaluated by the FDA and was determined to adequately convey safety and effectiveness information about the device … FDA worked with Bayer to incorporate the appropriate risk information in the labeling information for both physicians and patients. The agency wanted to ensure the boxed warning and Patient Decision Checklist [were] consistent with the final guidance," she said.
While the newly approved labeling has not been released by Bayer, Stark said that "Bayer has committed to posting their updated labeling as quickly as possible, and the FDA will provide links to the labeling on its website … as soon as the labeling is made public." Currently, FDA's webpage for Essure labeling information points to the company's 2015 labeling, as well as the product's original labeling from 2002.
According to Stark, FDA also approved a number of other changes included in Bayer's updated labeling for both physicians and patients:
"Physician instructions for use:
Patient labeling:
Tags: Essure, Boxed warning, Patient decision checklist
Regulatory Focus newsletters
All the biggest regulatory news and happenings.